Clinical Trials · NCT00667758

Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Betanien Hospital
Enrollment
104
Start date
May 2008
Locations
1 site, Norway
Primary endpoint
Change in Disease Activity Score (DAS28CRP) in cetrorelix group versus placebo group
View Gonadorelin compound reference